Division of Hematology and Medical Oncology, Weill-Medical College of Cornell University/New York Presbyterian Hospital, NY 10065, USA.
Expert Rev Hematol. 2013 Oct;6(5):611-24. doi: 10.1586/17474086.2013.840997. Epub 2013 Oct 4.
Several classification and scoring systems have been developed in myelodysplastic syndromes (MDS to predict the risk of progression to acute myeloid leukemia and survival. These prognostication models have been also used to inform therapeutic decision-making in a risk-adapted fashion. Patient-related factors such as age, comorbidities, and functional status have to be considered as well. Here we review a risk-guided therapeutic approach for the management of MDS patients. It is anticipated that the improved understanding of the complex pathogenesis of MDS and the recent discovery of important molecular lesions will be translated into novel therapeutic approaches. Additionally, some prognostic aberrations are expected to be incorporated into the prognostic tools with the goal of improving their prognostic precision and therefore allow for a more informed therapeutic decision-making based on the individual's risk profile.
几种分类和评分系统已在骨髓增生异常综合征 (MDS) 中开发出来，以预测向急性髓系白血病 (AML) 进展和生存的风险。这些预后模型也被用于以风险适应的方式为治疗决策提供信息。还需要考虑患者相关因素，如年龄、合并症和功能状态。在这里，我们回顾了一种针对 MDS 患者管理的风险导向治疗方法。预计对 MDS 复杂发病机制的深入了解和最近对重要分子病变的发现将转化为新的治疗方法。此外，一些预后异常预计将被纳入预后工具中，以提高其预后精度，从而根据个体的风险概况做出更明智的治疗决策。
